Multiple sclerosis Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Ant

Multiple sclerosis Pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple sclerosis treatment therapies, analyzes DelveInsight.

Multiple sclerosis Overview:

Multiple sclerosis (MS) is the most prevalent neurological condition affecting young adults, with symptoms typically appearing between the ages of 20 and 40. The disease targets the axons in the central nervous system, which are protected by myelin, commonly referred to as white matter.
The relapsing-remitting form of MS (RRMS) is the most widespread, accounting for around 85% of cases. This type is characterized by episodes of symptom flare-ups-also known as relapses or exacerbations-followed by periods of remission, during which symptoms partially or completely subside. There are also rarer forms of MS that present in less typical ways. Individuals with RRMS often experience recurring symptoms that may be linked to specific triggers.
Exacerbations, also called relapses or attacks, involve either the sudden worsening of existing symptoms or the onset of new symptoms that persist for at least 24 hours. These relapses are believed to result from the formation of new lesions or damage in the brain.
Early signs of MS may include:
Visual disturbances, such as blurred or double vision, or optic neuritis, which causes eye pain and sudden vision loss

Muscle weakness, particularly in the arms or legs, along with stiffness and painful muscle spasms

Tingling, numbness, or pain in the limbs, trunk, or face

Coordination and balance issues, such as clumsiness while walking

Bladder dysfunction

Occasional or persistent dizziness

These symptoms can vary greatly in severity and duration from person to person.

Download our report @ https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Multiple sclerosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Multiple sclerosis Therapeutics Market.

Key Takeaways from the Multiple sclerosis Pipeline Report

DelveInsight's Multiple sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Multiple sclerosis treatment.
In January 2025, the FDA issued a boxed warning for glatiramer acetate, marketed as Copaxone and its generic versions, due to reports of rare but serious allergic reactions, including anaphylaxis. Patients are advised to seek immediate medical attention if they experience symptoms such as difficulty breathing, swelling, or hives following an injection. ​
In September 2024, the FDA authorized the marketing of a new device intended as a short-term treatment to improve gait in MS patients experiencing mild to moderate symptoms. This device offers a non-pharmacological option to assist with mobility challenges associated with MS. ​
In August 2024, the FDA approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab), for the treatment of adults with relapsing forms of MS. This approval aims to enhance treatment accessibility and potentially reduce costs for patients. ​
Key Multiple sclerosis companies such as Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse, and others are evaluating new drugs for Multiple sclerosis to improve the treatment landscape.
Promising Multiple sclerosis pipeline therapies in various stages of development include IMU-838, BIIB091, IMCY-0141, NeuroVax, and others.

Multiple sclerosis Pipeline Analysis
The Multiple sclerosis pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Multiple sclerosis Market.

Categorizes Multiple sclerosis therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Multiple sclerosis drugs under development based on:

Stage of development

Multiple sclerosis Route of administration

Target receptor

Monotherapy vs. combination therapy

Multiple sclerosis Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Multiple sclerosis Licensing agreements

Funding and investment activities supporting future Multiple sclerosis market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Multiple sclerosis Emerging Drugs

IMU-838: Immunic Therapeutics
BIIB091: Biogen
IMCY-0141: ImCyse
NeuroVax: Immune Response BioPharma

Multiple sclerosis Companies

There are over 75 prominent companies actively involved in developing treatments for Multiple Sclerosis. Among them, Immunic Therapeutics has a drug candidate that has reached the most advanced development stage-Phase III clinical trials.
DelveInsight's report covers around 80+ products under different phases of Multiple sclerosis clinical trials like

Multiple sclerosis Late stage Therapies (Phase III)
Multiple sclerosis Mid-stage Therapies (Phase II)
Multiple sclerosis Early-stage Therapies (Phase I)
Multiple sclerosis Pre-clinical and Multiple sclerosis Discovery stage Therapies
Multiple sclerosis Discontinued & Inactive Therapies

Multiple sclerosis pipeline report provides the Multiple sclerosis therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Multiple sclerosis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Multiple sclerosis Therapies and Key Multiple sclerosis Companies: Multiple sclerosis Clinical Trials and recent advancements https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Multiple sclerosis Pipeline Therapeutic Assessment
• Multiple sclerosis Assessment by Product Type
• Multiple sclerosis By Stage
• Multiple sclerosis Assessment by Route of Administration
• Multiple sclerosis Assessment by Molecule Type

Download Multiple sclerosis Sample report to know in detail about the Multiple sclerosis treatment market @ Multiple sclerosis Therapeutic Assessment https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Multiple sclerosis Current Treatment Patterns
4. Multiple sclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Multiple sclerosis Late-Stage Products (Phase-III)
7. Multiple sclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Multiple sclerosis Discontinued Products
13. Multiple sclerosis Product Profiles
14. Multiple sclerosis Key Companies
15. Multiple sclerosis Key Products
16. Dormant and Discontinued Products
17. Multiple sclerosis Unmet Needs
18. Multiple sclerosis Future Perspectives
19. Multiple sclerosis Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Multiple sclerosis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.